Table 1 Summary of descriptive characteristics of cohort
From: Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study
Unvaccinated | Vaccinated, Any dose | Vaccinated, 1 dose | Vaccinated, 2 doses | Completely vaccinated, 3 doses | |
|---|---|---|---|---|---|
Number of observations | 14,085 | 24,871 | 1,422 | 2,268 | 21,151 |
Mean age in 2007 | 16.1 (± 1.0) | 16.0 (± 1.0)* | 16.0 (± 1.0) | 16.0 (± 1.0)# | 16.0 (± 1.0) |
Mean age at first screen | 18.5 (± 1.4) | 18.5 (± 1.3)# | 18.1 (± 1.5)# | 18.1 (± 1.5)# | 18.6 (± 1.3) |
Mean age at entry to cohort | 19.0 (± 1.4) | 19.0 (± 1.3) | 18.7 (± 1.3)# | 18.7 (± 1.3)# | 19.0 (± 1.2)# |
Age in 2007 (years) | |||||
≤14 | 1,446 (10.3%) | 2,567 (10.3%) | 163 (11.5%) | 271 (11.9%)* | 2,131 (10.1%) |
15 | 2,434 (17.3%) | 4,480 (18.0%) | 262 (18.4%) | 470 (20.7%)# | 3,743 (17.7%) |
16 | 4,125 (29.3%) | 7,419 (29.8%) | 372 (26.2%)+ | 628 (27.7%) | 6,413 (30.3%)* |
17 | 6,080 (43.2%) | 10,405 (41.8%)+ | 625 (44.0%) | 899 (39.6%)+ | 8,864 (41.9%)* |
Remoteness area 3 | |||||
Major cities | 10,019 (71.8%) | 16,608 (66.8%)# | 955 (67.2%)# | 1,477 (65.1%)# | 14,154 (67.0%)# |
Inner regional | 3,250 (23.3%) | 6,858 (27.6%)# | 383 (26.9%)# | 642 (28.3%)# | 5,826 (27.6%)# |
Outer regional | 681 (4.9%) | 1,380 (5.6%)+ | 83 (5.8%) | 147 (6.5%)# | 1,149 (5.4%)+ |
Remote | 6 (0.0%) | 14 (0.1%) | 1 (0.1%) | 2 (0.1%) | 11 (0.1%) |
Socioeconomic status 4 | |||||
1 (lowest) | 2,551 (18.4%) | 3,830 (15.5%)# | 278 (19.6%) | 401 (17.7%) | 3,147 (14.9%)# |
2 | 2,833 (20.4%) | 4,741 (19.1%)+ | 336 (23.7%)+ | 497 (22.0%)* | 3,899 (18.5%)# |
3 | 2,713 (19.6%) | 4,463 (18.0%)# | 262 (18.5%) | 444 (19.7%) | 3,754 (17.8%)# |
4 | 3,195 (23.1%) | 6,340 (25.6%)# | 302 (21.3%) | 572 25.3%)+ | 5,461 (25.9%)# |
5 (highest) | 2,571 (18.6%) | 5,399 (21.8%)# | 240 (16.9%) | 346 (15.3%)# | 4,804 (22.8%)# |
Age at first screen (years) | |||||
≤14 | 105 (0.7%) | 114 (0.5%)# | 13 (0.9%) | 30 (1.3%)+ | 71 (0.3%)# |
15 to 17 | 2,831 (20.1%) | 4,840 (19.5%) | 436 (30.7%)# | 624 (27.5%)# | 3,775 (17.8%)# |
18+ | 11,149 (79.2%) | 19,917 (80.1%)* | 973 (68.4%)# | 1,614 (71.2%)# | 17,305 (81.8%)# |
Screening history | |||||
Screening before 1 April 2007 | 244 (1.7%) | 385 (1.5%) | 52 (3.7%)# | 74 (3.3%)# | 257 (1.2%)# |
First screen after 1 April 2007 | 13,841 (98.3%) | 24,486 (98.5%) | 1,370 (96.3%)# | 2,194 (96.7%)# | 20,894 (98.8%)# |
Age commenced vaccination (years) | |||||
≤13 | 591 (2.4%) | 19 (1.3%)! | 63 (2.8%) | 509 (2.4%) | |
14 to 15 | 9,609 (38.6%) | 318 (22.4%)$ | 756 (33.3%)$ | 8,526 (40.3%) | |
16 to 17 | 13,519 (54.4%) | 679 (47.7%)$ | 1,159 (51.1%)$ | 11,665 (55.2%) | |
18+ | 1,152 (4.6%) | 406 (28.6%)$ | 290 (12.8%)$ | 451 (2.1%) | |
Year entered cohort | |||||
2007 | 632 (4.5%) | 497 (2.0%)# | 46 (3.2%)* | 52 (2.3%)# | 398 (1.9%)# |
2008 | 1,114 (7.9%) | 2,140 (8.6%)* | 188 (13.2%)# | 248 (10.9%)# | 1,701 (8.0%) |
2009 | 2,350 (16.7%) | 4,924 (19.8%)# | 357 (25.1%)# | 577 (25.4%)# | 3,982 (18.8%)# |
2010 | 3,981 (28.3%) | 7,375 (29.7%)+ | 403 (28.3%) | 607 (26.8%) | 6,361 (30.1%)# |
2011 | 6,008 (42.7%) | 9,935 (39.9%)# | 428 (30.1%)# | 784 (34.6%)# | 8,709 (41.2%)+ |
Cytological abnormalities diagnosed on entry into cohort 5 | |||||
Negative | 11,444 (82.7%) | 19,661 (85.4%)# | 911 (80.5%)# | 1,579 (84.1%)# | 17,148 (85.7%) |
Low-grade | 1,817 (13.1%) | 2,488 (10.8%)# | 169 (14.9%) | 230 (12.2%)# | 2,086 (10.4%)# |
High-grade | |||||
Possible | 111 (0.8%) | 146 (0.7%)* | 8 (0.7%) | 15 (0.8%) | 123 (0.6%)* |
Definite | 97 (0.7%) | 132 (0.6%)* | 12 (1.1%) | 12 (0.6%) | 108 (0.5%)* |
Endocervical | 1 (0.0%) | 4 (0.0%) | 0 (0.0%) | 0 (0.0%) | 4 (0.0%) |